# Forensic Dossier: Study Forensics: APJ agonist as pharmacological exercise mimetic

**Run ID:** `full27_study-forensics-030_Claude_Haiku_f96b63`  
**Task:** study-forensics-030 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:05:36.658851+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** preclinical_to_therapeutic_leap  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **73.1/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 4
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 5.6/8 | 8.0/8 | 1.5/10 | 8.5/10 | **73.1/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `mechanism_vs_evidence` [+] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** cautious_scope_control, none_or_minor, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "mechanism_vs_evidence"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[3]`: "4. HEDGE ANALYSIS: The text contains no explicit uncertainty language ('may,' 'could,' 'preliminary'). The framing is co"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "The text implies readiness for human translation without intermediate biomarker or limited human evidence"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[0]`: "Whether the company's internal data includes any human biomarker studies (e.g., receptor occupancy, pathway activation i"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[1]`: "OVERCLAIM (considered but rejected as less precise): The issue is not primarily that claims are too strong in tone, but "
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[2]`: "Did I confuse 'the study is well-designed' with 'the claims are appropriate'? Yes, I should note: the mouse studies may "
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.70, 702 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength, structural_reasoning_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/12 content words)
  - `key_claims[0]`: "CRITICAL: Animal data (mice) are being used to support human therapeutic claims without intermediate"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/11 content words)
  - `key_claims[1]`: "CRITICAL: The combination therapy result (incretin + agonist) is shown only in mice; synergy in huma"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/13 content words)
  - `key_claims[2]`: "IMPORTANT: The 'exercise mimetic' framing is mechanistic and requires human validation of both pathw"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/14 content words)
  - `key_claims[3]`: "IMPORTANT: No discussion of known limitations in translating mouse metabolic disease to humans (micr"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/9 content words)
  - `key_claims[4]`: "MODERATE: The cardiac hypertrophy results in a heart-failure model are promising but also animal-onl"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "mechanism_vs_evidence"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 17301ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.88

**Assumptions:**
- The study involved mouse models of obesity, diabetes, and heart failure (not human subjects)
- The company is making claims about human therapeutic potential based on animal data
- The text implies readiness for human translation without intermediate biomarker or limited human evidence
- Apelin/APJ pathway biology in mice is assumed to translate to humans
- The combination therapy results in mice are assumed to predict human outcomes

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: The reported results are from preclinical studies in obese/diabetic mice and heart-failure models. This is animal-model evidence (tier 2).
2. 2. CONCLUSION TIER IDENTIFICATION: The company claims the approach 'could serve as a pharmacological exercise mimetic' and is 'preparing to translate into human trials.' This language implies human therapeutic benefit (tier 5 conclusion).
3. 3. BRIDGE GAP DETECTION: There is a direct leap from animal models (tier 2) to human therapeutic claims (tier 5). No intermediate biomarker studies, pilot human data, or mechanistic validation in human tissue is mentioned.
4. 4. HEDGE ANALYSIS: The text contains no explicit uncertainty language ('may,' 'could,' 'preliminary'). The framing is confident: 'improved,' 'reduced,' 'restored,' 'preparing to translate.' The absence of hedging makes the tier mismatch more pronounced.
5. 5. MECHANISM CLAIM: The company frames this as an 'exercise hormone' system and 'exercise mimetic'—a mechanistic claim that requires human validation. The pathway activation is demonstrated in mice, but human efficacy and safety are not addressed.
6. 6. COMBINATION THERAPY CONCERN: The synergy with incretin therapy (nearly doubled weight loss) is shown only in mice. Combination effects are notoriously difficult to predict in humans and require separate human evidence.
7. 7. CONFOUNDERS NOT ADDRESSED: Mouse models of obesity and diabetes differ substantially from human disease in metabolic regulation, microbiota, genetics, and drug metabolism. No discussion of these limitations.

**Key Claims:**
- CRITICAL: Animal data (mice) are being used to support human therapeutic claims without intermediate human evidence.
- CRITICAL: The combination therapy result (incretin + agonist) is shown only in mice; synergy in humans is unvalidated.
- IMPORTANT: The 'exercise mimetic' framing is mechanistic and requires human validation of both pathway activation and functional outcomes.
- IMPORTANT: No discussion of known limitations in translating mouse metabolic disease to humans (microbiota, genetics, drug metabolism differences).
- MODERATE: The cardiac hypertrophy results in a heart-failure model are promising but also animal-only evidence.

**Alternative Hypotheses:**
- SOLID (rejected): If the text had explicitly stated 'preclinical mouse data suggest potential for human trials' with clear caveats about the need for human validation, this could be solid. But the confident framing and direct translation claim exceed the evidence.
- OVERCLAIM (considered but rejected as less precise): The issue is not primarily that claims are too strong in tone, but that they jump evidence tiers. Overclaim would apply if human efficacy were claimed with certainty; here, the problem is the tier mismatch itself.
- CORRELATION_VS_CAUSATION (rejected): The study appears to be mechanistic (drug given, outcomes measured), not observational. Causation is reasonably inferred within the animal model.

**Uncertainties:**
- Whether the company's internal data includes any human biomarker studies (e.g., receptor occupancy, pathway activation in human tissue) not mentioned in this summary.
- Whether 'preparing to translate' means IND-enabling studies are underway or if human trials are imminent—this affects the urgency of the evidence gap.
- The quality of the mouse models: are they well-validated models of human disease, or simplified systems? This affects the strength of the bridge.
- Whether the apelin/APJ pathway has been previously validated in human studies (it has been studied, but efficacy data in humans is limited).

**Self-Verification:**
- Did I overstate the problem? No—the text explicitly states mouse studies and human translation plans. The tier mismatch is real.
- Did I miss that this is a solid study? No—solid would require human data or explicit, prominent hedging. The confident framing and direct translation claim indicate mechanism_vs_evidence.
- Did I confuse 'the study is well-designed' with 'the claims are appropriate'? Yes, I should note: the mouse studies may be well-executed, but the conclusions exceed the evidence tier. A well-designed animal study is still animal-tier evidence.
- Is the hedge 'preparing to translate' sufficient? No—acknowledging the next step does not resolve the current tier mismatch. The text still implies human benefit based on animal data.
- Should I flag this as overclaim instead? Mechanism_vs_evidence is more precise because the core issue is the evidence tier, not the tone of the claims.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **73.1/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 17.3s | 73.1/100 | 4.2 |

Failure modes observed: named_not_explained, unsupported_conclusion, unsupported_intermediate_step.
